Treatment for Aortic Valve Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Aortic Valve Disease+3 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying the Trifecta valve, which is used to treat heart valve disease. They are following patients for 5 years to see how well it works and if it is safe.

Eligible Conditions
  • Aortic Valve Disease
  • Aortic valve disorder
  • Aortic Valve Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Aortic Valve Disease

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 5 years post implant

5 years post implant
Freedom from all-cause mortality
Freedom from structural valve deterioration
Freedom from surgical valve replacement or transcatheter valve implantation due to structural valve deterioration
Freedom from surgical valve replacement or transcatheter valve-in-valve implantation
Freedom from valve related mortality
Year 5
Valve hemodynamic performance

Trial Safety

Safety Progress

1 of 3

Other trials for Aortic Valve Disease

Trial Design

0 Treatment Group

363 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years post implant

Who is running the clinical trial?

Abbott Medical DevicesLead Sponsor
599 Previous Clinical Trials
362,888 Total Patients Enrolled
6 Trials studying Aortic Valve Disease
2,822 Patients Enrolled for Aortic Valve Disease

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The subject must be willing and able to provide written consent to participate in this study.
The subject is a candidate for surgery to replace their aortic valve, and they are expected to have a St
The person is of legal age in the country where they are studying.
The subject must be willing and able to comply with all follow-up requirements.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: October 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.